BACKGROUND: The combination of increased cardiovascular mortality and vascular complications due to dyslipidaemia in chronic kidney disease (CKD) has focused attention onto the potential beneficial effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA) inhibitors (statins) on the course of CKD. OBJECTIVE: To examine the use of statins in CKD. METHODS: A review of relevant literature. RESULTS/ CONCLUSION: Current evidence from clinical trials in CKD patients on maintenance dialysis is limited. Therefore, the routine use of statins in this population remains the decision of individual physicians in discussion with their patients.
BACKGROUND: The combination of increased cardiovascular mortality and vascular complications due to dyslipidaemia in chronic kidney disease (CKD) has focused attention onto the potential beneficial effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA) inhibitors (statins) on the course of CKD. OBJECTIVE: To examine the use of statins in CKD. METHODS: A review of relevant literature. RESULTS/ CONCLUSION: Current evidence from clinical trials in CKDpatients on maintenance dialysis is limited. Therefore, the routine use of statins in this population remains the decision of individual physicians in discussion with their patients.
Authors: Anna Gluba; Maciej Banach; Simon Hannam; Dimitri P Mikhailidis; Agata Sakowicz; Jacek Rysz Journal: Nat Rev Nephrol Date: 2010-02-23 Impact factor: 28.314
Authors: Kosmas I Paraskevas; Ioannis Kotsikoris; Sotirios A Koupidis; Alexandros A Tzovaras; Dimitri P Mikhailidis Journal: Int Urol Nephrol Date: 2010-06-24 Impact factor: 2.370
Authors: Jacek Rysz; Maciej Banach; Robert A Stolarek; Dimitri P Mikhailidis; Aleksandra Cialkowska-Rysz; Lech Pokoca; Mariusz Piechota; Zbigniew Baj Journal: Int Urol Nephrol Date: 2009-12-02 Impact factor: 2.370